Emerging Tumor Biomarkers in Pancreatic Cancer and Their Clinical Implications
Dimitrios Stefanoudakis(APLA Health), Konstantinos G. Toutouzas(National and Kapodistrian University of Athens), Nikolaos V. Michalopoulos(National and Kapodistrian University of Athens), Dimitriοs Schizas(National and Kapodistrian University of Athens), Maximos Frountzas(National and Kapodistrian University of Athens), Dimitrios Theodorou(National and Kapodistrian University of Athens)
Cited by 2
Related Papers
Significance of TP53, CDKN2A, SMAD4 and KRAS in Pancreatic Cancer
|Current Issues in Molecular Biology|2024|78
Immunotherapy in Cervical and Endometrial Cancer: Current Landscape and Future Directions
|Life|2024|25
VEGF inhibition in urothelial cancer: the past, present and future
|World Journal of Urology|2020|19